J Clin Neurosci
September 2025
Background: Meningiomas exhibit considerable phenotypic variation within each WHO grade, thus additional markers are needed to identify prognostically relevant subgroups and optimize long-term management. Among biomarkers, genetic signatures correlate with prognoses. High Ki-67 proliferation indices and TERT promotor mutations and loss of CDKNA are known prognostic markers.
View Article and Find Full Text PDFBackground: Current challenges in meningioma treatment, including post-surgical complications and cognitive impairments, highlight the need for new treatment alternatives. Immunological interventions have shown promise. However, there is a knowledge gap in characterizing infiltrating immune cells in meningioma and their interplay.
View Article and Find Full Text PDFJ Neuropathol Exp Neurol
November 2023
Meningiomas are the most common primary intracranial tumors and show extensive infiltration of macrophages. The mitochondrial membrane protein translocator protein (TSPO) has been used as an in vivo marker of microglia and macrophage activation to visualize neuroinflammation. However, it is unknown which cell types express TSPO in meningiomas.
View Article and Find Full Text PDF